Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

139 results about "Transplanted Organs" patented technology

Monitoring, preventing, and treating rejection of transplanted organs

An implantable system control unit (SCU) includes means for measuring tissue impedance or other condition to determine allograft health, in order to predict or detect allograft rejection. The SCU also includes at least two electrodes coupled to means for delivering electrical stimulation to a patient within whom the device is implanted, and may also include a reservoir for holding one or more drugs and a driver means for delivering the drug(s) to the patient. In certain embodiments, the system is capable of open- and closed-loop operation. In closed-loop operation, at least one SCU includes a sensor, and the sensed condition is used to adjust stimulation parameters. Alternatively, this sensory “SCU” sounds an alarm, communicates an alarm to an external device, and / or is responsive to queries regarding sensed information, such as tissue impedance.
Owner:BOSTON SCI NEUROMODULATION CORP

Method for the early detection of breast cancer, lung cancer, pancreatic cancer and colon polyps, growths and cancers as well as other gastrointestinal disease conditions and the preoperative and postoperative monitoring of transplanted organs from the donor and in the recipient and their associated conditions related and unrelated to the organ transplantation

A method for the early diagnosis of breast, lung, pancreatic and colon growths and cancers as well as conditions associated with donor and recipient organ transplants, both before and after transplantation to identify and allow treatment of possible transplanted organ rejection and other disease conditions related and unrelated to the transplantation, compares the gene expression patterns from a patient's peripheral blood monocytes-lymphocyte's gene system with either the similar gene expression patterns of a normal person, or with the similar gene expression patterns of a person known to have the condition being screened for. Differences between the patient's gene expression patterns for particular genes and the normal patterns indicates the presence of the condition with the number of differences indicating the probability of the condition. Similarities between the patient's gene expression patterns for those particular genes and the patterns of a person known to have the condition indicates the presence of the condition with the number of similarities indicating the probability of the condition. For example, particular genes for use in identifying pancreatic cancer are disclosed.
Owner:BAUER A ROBERT

Hetero ring derivative

[Object]A novel and excellent method for preventing or treating rejection in the transplantation of various organs, allergy diseases, autoimmune diseases, hematologic tumor, or the like, based on a PI3Kδ-selective inhibitory action and / or an IL-2 production inhibitory action, and / or a B cell proliferation inhibitory action (including an activation inhibitory action), is provided[Means for Solution]It was found that a 3-substituted triazine or 3-substituted pyrimidine derivative exhibits a PI3Kδ-selective inhibitory action, and / or an IL-2 production inhibitory action, and / or a B cell proliferation inhibitory action (including an activation inhibitory action), and can be an agent for preventing or treating rejection in the transplantation of various organs, allergy diseases (asthma, atopic dermatitis, etc.), autoimmune diseases (rheumatoid arthritis, psoriasis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, etc.), hematologic tumor (leukemia etc.), or the like, thereby completing the present invention.
Owner:ASTELLAS PHARMA INC

Quantification of Adaptive Immune Cell Genomes in a Complex Mixture of Cells

Compositions and methods are described for highly sensitive quantification of the relative representation of DNA from adaptive immune cells (e.g., T and / or B lymphocytes) in DNA extracted from complex mixtures of cells that include cells which are not adaptive immune cells. Included are methods for determining the relative presence in a tumor of tumor infiltrating lymphocytes (TIL), the relative presence of lymphocytes infiltrating a somatic tissue that is the target of an autoimmune disease, and the relative presence of lymphocytes infiltrating a transplanted organ.
Owner:ADAPTIVE BIOTECH +1

Apparatus and method for preventing adhesions between an implant and surrounding tissues

An anti-adhesion membrane is placed onto an implant introduced into a surgical site of a patient to prevent post-surgical adhesions between the implant and surrounding tissue. The implant may comprise either biological material, such as a transplanted organ, or non-biological material such as a medical device. The membrane may be applied in a variety of ways. In one example, a membrane according to the present invention is shrink-wrapped around a pace-maker. In another example, a breast implant is spray-coated or dipped with the membrane material.
Owner:MAST BIOSURGERY

Methods and Compositions for Modulating the Immune System with Arginase I

ActiveUS20150315561A1Nervous disorderPeptide/protein ingredientsTransplanted OrgansPlasma arginine level
Methods and compositions comprising recombinant Arginase I proteins which are capable of depleting the plasma arginine levels in a subject are disclosed. The methods and compositions can be used to modulate the activity of the immune system in a subject. Modulation of the immune system is useful in the treatment of immune disorders and in preventing rejection of a transplanted organ, tissue, or cell. The methods and compositions can also be used to treat a bone condition of a subject.
Owner:BIO CANCER TREATMENT INT

Method of producing progenitor cells from differentiated cells

The present invention provides a method of producing progenitor cells, such as cells capable of being differentiated into a plurality of different cell types, from differentiated cells. Methods of using progenitor cells in differentiation and / or tissue or organ repair and / or regeneration and / or building are also provides. Methods of using progenitor cells in treatment and prophylaxis of conditions alleviated by administering stem cells or tissue or organ derived from stem cells to a subject or by grafting stem cells or tissue or organ derived from stem cells into a subject or by transplanting stem cells or tissue or organ derived from stem cells into a subject are also provided. Also included are progenitor cells and differentiated cells and / or tissues and / or organs derived therefrom, and kits comprising same.
Owner:REGENERTECH

Monitoring, preventing, and treating rejection of transplanted organs

An implantable system control unit (SCU) includes means for measuring tissue impedance or other condition to determine allograft health, in order to predict or detect allograft rejection. The SCU also includes at least two electrodes coupled to means for delivering electrical stimulation to a patient within whom the device is implanted, and may also include a reservoir for holding one or more drugs and a driver means for delivering the drug(s) to the patient. In certain embodiments, the system is capable of open- and closed-loop operation. In closed-loop operation, at least one SCU includes a sensor, and the sensed condition is used to adjust stimulation parameters. Alternatively, this sensory “SCU” sounds an alarm, communicates an alarm to an external device, and / or is responsive to queries regarding sensed information, such as tissue impedance.
Owner:BOSTON SCI NEUROMODULATION CORP

Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor

InactiveUS20050043355A1BiocideNervous disorderLeukotriene-A4 hydrolaseAutoimmune condition
Treatment with a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor is described as being useful in reducing recipient rejection of transplanted organs and for treatment of autoimmune diseases.
Owner:PHARMACIA CORP

Cell Population Having Immunoregulatory Activity, Method for Isolation and Uses

The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-γ) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.
Owner:TIGENIX SAU +1

Methods and devices for tissue monitoring

The present invention is directed to a system and method for monitoring the physiological parameters of an organ or tissue during and after surgery. The system has a probe and a monitoring unit. In one embodiment the probe includes features for convenient, fixed and releasable attachment to surgical drains without interfering with their normal fluid-draining function while utilizing their suction to enhance the probe-to-tissue interface for improved sensing. An applicator is provided to facilitate such attachment. The monitoring unit which controls the sensors of the probe includes a processor to process, record and display the sensor data. This system may be valuable for monitoring transplanted organs and tissue grafts during the critical postoperative period when most of the clinical complications, such as vascular thrombosis, may occur.
Owner:MANSOUR HEBAH NOSHY +1

Nucleic acids encoding a chimeric glycosyltransferase

The invention relates to nucleic acids which encode glycosyltransferase and are useful in producing cells and organs from one species which may be used for transplantation into a recipient of another species. It also relates to the production of nucleic acids which, when present in cells of a transplanted organ, result in reduced levels of antibody recognition of the transplanted organ.
Owner:THE AUSTIN RES INST

Method to assess human allograft status from microrna expression levels

The invention relates to, among other things, a method for assessing risk of organ rejection in a patient having a transplanted organ. The method includes measuring an amount of expression of a small non-coding marker RNA in a biological sample from the patient. The method further includes comparing the measured amount of expression of the small non-coding marker RNA in the patient to a reference amount of expression of the small non-coding marker RNA. In another aspect, the invention relates to kits for assessing risk of organ rejection in a patient having a transplanted organ.
Owner:CORNELL UNIVERSITY

Sub normal temperature transplanted organ extracorporal intelligent support system and method

ActiveCN104705288AHighly integratedTaking into account the needs of immunobiological modification operationsDead animal preservationHuman bodyFeedback control
The invention discloses a sub normal temperature transplanted organ extracorporal intelligent support system and method. The system mainly comprises a sensor acquisition module, a perfusion / oxygenation module, a safety protection module, a man-machine interaction module, a data storage and analysis module, a network module, a power management module and a central control module. According to the invention, intracorporal physiological simulation of full-simulation pulsating wave perfusion, temperature control and oxygenation supply combination is constructed, and various sensors are coordinated to monitor various life indicators, so that multifunctional and multiparameter intelligent storage of an organ is realized. The method is designed according to extracorporal storage characteristics of the transplanted organ and comprises analysis of organ real-time physiological parameter, intelligent feedback adjustment and control of perfusion / oxygenation, failure alarm and safety protection, network data sharing and remote control, and safe and effective long-time storage can be realized. The system adopts the full-simulation pulsating wave perfusion and dynamic simulation feedback control technologies; the perfusion pressure is closer to that of a human body, the parameter adjustment and control are more accurate, and the range is wider.
Owner:HANGZHOU DIANZI UNIV

Fibrosis inhibitor for implanted organ

A pharmaceutical preparation comprising a hepatocyte growth factor or a DNA molecule encoding the same and the like according to the present invention can suppress the fibrosis of a transplanted organ after organ transplantation. The present invention is useful in the fields of organ transplantation and regeneration therapy.
Owner:KRINGLE PHARMA INC

[1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof

InactiveUS20070010515A1Suppression problemSuppresses lymphocyte proliferation responseOrganic active ingredientsBiocideGraft versus host reactionsAutoimmune condition
Novel [1,2,4]triazolo[1,5-a]pyrimidine derivative of the general formula (1): (1) its prodrug or a pharmaceutically acceptable salt thereof, which exhibits an antigen presentation inhibiting activity and is useful as a preventive and / or therapeutic agent for immunological rejection and / or graft versus host reaction in organ / bone marrow transplant, autoimmune disease, allergic disease and / or inflammatory disease and also useful as an anticancer drug or as an immunological tolerance inducer for transplanted organ / transplanted bone marrow.
Owner:NIPPON KAYAKU CO LTD +1

Methods of Using FOXP3 Levels to Predict the Outcome of Organs Undergoing Acute Rejection

A method for assessing risk of losing a transplanted organ by a patient having an episode of acute rejection of the transplanted organ is described. The method includes obtaining from the patient a cell sample from the transplanted organ or peripheral blood, determining a level of FOXP3 in the cell sample, and correlating the level with the risk of loss of the transplanted organ, wherein, compared to a control level, a significantly greater level of FOXP3 in the cell sample from the transplanted organ or a significantly lower level of FOXP3 in the cell sample from the peripheral blood correlates with a decreased risk of loss of the transplanted organ.
Owner:CORNELL RES FOUNDATION INC

Method for the early detection of breast cancer, lung cancer, pancreatic cancer and colon polyps, growths and cancers as well as other gastrointestinal disease conditions and the preoperative and postoperative monitoring of transplanted organs from the donor and in the recipient and their associated conditions related and unrelated to the organ transplantation

A method for the early diagnosis of breast, lung, pancreatic and colon growths and cancers as well as conditions associated with donor and recipient organ transplants, both before and after transplantation to identify and allow treatment of possible transplanted organ rejection and other disease conditions related and unrelated to the transplantation, compares the gene expression patterns from a patient's peripheral blood monocytes-lymphocyte's gene system with either the similar gene expression patterns of a normal person, or with the similar gene expression patterns of a person known to have the condition being screened for. Differences between the patient's gene expression patterns for particular genes and the normal patterns indicates the presence of the condition with the number of differences indicating the probability of the condition. Similarities between the patient's gene expression patterns for those particular genes and the patterns of a person known to have the condition indicates the presence of the condition with the number of similarities indicating the probability of the condition. For example, particular genes for use in identifying pancreatic cancer are disclosed.
Owner:BAUER A ROBERT

Gold nanorod with surface finish rosinyl quaternary ammonium salt molecules and preparation method and application thereof

InactiveCN104001932AWith near-infrared photothermal conversion effectBiologically activeAntibacterial agentsMaterial nanotechnologyMedical equipmentDrug biological activity
Provided are a gold nanorod with surface finish rosinyl quaternary ammonium salt molecules and a preparation method and application thereof. The preparation method comprises a first step of preparation of the rosinyl quaternary ammonium salt molecules, a second step of preparation of gold nanorod solution, a third step of preparation of the gold nanorod with the surface finish rosinyl molecules, wherein the third step comprises the substeps of enabling the obtained 6-7 mL of gold nanorod solution to undergo ultrasonic treatment for 20 min, adding the prepared rosinyl quaternary ammonium salt molecules of 0.014 g, performing ultrasonic treatment, standing the solution for 2-3 days under the water bath conditions of 35-40 DEG C, and finally obtaining the brown red solution which is the 2 mg / mL gold nanorod solution with the surface finish rosinyl quaternary ammonium salt molecules. The gold nanorod with the surface finish rosinyl quaternary ammonium salt molecules has a near-infrared photothermal conversion effect, can be applied to the fields of bacterial resistance, organ transplantation and medical equipment and have biological activities of bacterial resistance and cancer resistance.
Owner:珠海菲伯过滤材料有限公司

Methods and compositions for reducing injury to a transplanted organ

Methods for reducing injury to a transplanted mammalian organ or tissue, including inhibiting the development of graft blood vessel disease, are provided. In one form, a method includes administering compositions that include one or more PKC regulators to an organ or tissue donor and an organ or tissue recipient. Methods for decreasing or otherwise modulating an inflammatory response in a mammal are also provided. In one form, a method includes administering one or more regulators of protein kinase C to a patient in need thereof prior to, during or after an event giving rise to an inflammatory response. Methods for inhibiting, or otherwise modulating, a pro-apoptotic event are also provided. In one form, a method includes administering a therapeutically effective amount of an agonist of ε protein kinase C, and optionally an inhibitor of δ protein kinase C.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant

Methods of prolonging survival of a transplanted organ, as well as methods of preventing or attenuating rejection of a transplanted organ are provided. These methods involve contacting the organ with an inhibitor of complement activity (e.g., a complement inhibitor that has a maximum molecular weight of 70 kDa and / or a half-life shorter than 10 days, such as a CR2-FH fusion protein or a single chain anti-C5 antibody), prior to transplantation The methods also include administering to the allotransplant recipient an inhibitor of complement activity together with one or more immunosuppressants. A pretreatment with an alternative complement inhibitor was found to be effective in improving graft survival and decreasing ischemia-reperfusion injury in animal.
Owner:ALEXION PHARMA INC

Method of Producing Progenitor Cells from Differentiated Cells

ActiveUS20110111030A1Reduce and eliminate scar tissueIncrease differentiationPowder deliveryBiocideProgenitorOrgan transplantation
The present invention provides a method of producing progenitor cells, such as cells capable of being differentiated into a plurality of different cell types, from differentiated cells. Methods of using progenitor cells in differentiation and / or tissue or organ repair and / or regeneration and / or building are also provides. Methods of using progenitor cells in treatment and prophylaxis of conditions alleviated by administering stem cells or tissue or organ derived from stem cells to a subject or by grafting stem cells or tissue or organ derived from stem cells into a subject or by transplanting stem cells or tissue or organ derived from stem cells into a subject are also provided. Also included are progenitor cells and differentiated cells and / or tissues and / or organs derived therefrom, and kits comprising same.
Owner:REGENERTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products